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Infection of T cells by HIV-1 can occur through binding of virus to dendritic cell (DC)-specific ICAM-3 grabbing
nonintegrin (DC-SIGN) on dendritic cells and transfer of virus to CD4
þ T cells. Here we show that a subset of B cells in
the blood and tonsils of normal donors expressed DC-SIGN, and that this increased after stimulation in vitro with
interleukin 4 and CD40 ligand, with enhanced expression of activation and co-stimulatory molecules CD23, CD58,
CD80, and CD86, and CD22. The activated B cells captured and internalized X4 and R5 tropic strains of HIV-1, and
mediated trans infection of T cells. Pretreatment of the B cells with anti–DC-SIGN monoclonal antibody blocked trans
infection of T cells by both strains of HIV-1. These results indicate that DC-SIGN serves as a portal on B cells for HIV-1
infection of T cells in trans. Transmission of HIV-1 from B cells to T cells through this DC-SIGN pathway could be
important in the pathogenesis of HIV-1 infection.
Citation: Rappocciolo G, Piazza P, Fuller CL, Reinhart TA, Watkins SC, et al. (2006) DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS
Pathog 2(7): e70. DOI: 10.1371/journal.ppat.0020070
Introduction
HIV-1 can bind to the type II C-type lectin receptor,
dendritic cell (DC)-speciﬁc ICAM-3 grabbing nonintegrin
(DC-SIGN; CD209), on myeloid DC and be transferred to
CD4
þ T cells [1,2]. An important feature of this trans pathway
is that the virus does not establish an efﬁcient, productive
infection in these DC. Rather, it is captured by the DC and
internalized in distinct intracellular compartments, and then
transmitted to CD4
þ T cells wherein it undergoes productive
replication [3]. This is considered to be an alternative
pathway to HIV-1 cis infection of T cells, macrophages, and
DC that occurs through binding to the primary CD4 receptor
and either of the chemokine coreceptors CXCR4 or CCR5.
B lymphocytes have also been implicated in trans infection
of T cells with HIV-1 [4]. Given the intimate association of B
cells and T cells in lymphoid tissue, B cell–mediated trans
infection pathways could be important in the spread of virus
to T cells. B cells derived either from lymphoid tissue or from
the peripheral blood of HIV-1–infected persons carry
replication-competent virus of either the CXCR4 (X4) or
CCR5 (R5) tropic strain [5]. The mechanism by which B cells
have been shown to transmit the virus involves binding of
HIV-1 immune complexes to CR2 or CD21 on the surface of
B cells and subsequent passage to the T cells [6–10]. Other
reports have proposed a role for B cells in HIV-1 infection
involving B cell activation processes induced by nef-express-
ing macrophages [11].
B cells express some C-type lectin receptors [12–15], with
conﬂicting reports on expression of DC-SIGN [16,17]. Trans-
fer of HIV-1 by B cells via a C-type lectin receptor pathway
described for DC could be of signiﬁcance in HIV-1 patho-
genesis. We therefore investigated B cells for a DC-SIGN–
mediated, trans pathway for HIV-1 infection of CD4
þ T cells.
We found that a subset of B cells in the peripheral blood and
tonsils of healthy, HIV-1 seronegative donors expressed DC-
SIGN, and that DC-SIGN expression increased after stim-
ulation with interleukin 4 (IL-4) and CD40 ligand (CD40L).
The stimulated, DC-SIGN
þ B cells mediated trans infection of
T cells.
Results
DC-SIGN Expression in B cells and Enhancement by
Stimulation with IL-4 and CD40L
Our initial, three-color ﬂow cytometric analysis of periph-
eral blood mononuclear cells (PBMC) showed that DC-SIGN
was expressed on a small but distinct subset of CD19
þ B cells
within the CD45
þ/CD19
þ gated population of PBMC of
normal, HIV-1–negative persons (representative example,
Figure 1A). To extend this ﬁnding, we analyzed DC-SIGN
expression on B cells that were puriﬁed from PBMC of 33
normal donors by sorting with anti-CD19 monoclonal anti-
body (mAb)-coated magnetic beads. Flow cytometric results
showed that DC-SIGN was expressed on 7.9 6 1.8% (mean 6
standard error [SE]) of puriﬁed, peripheral blood CD20
þ B
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results, Figure 1C, T0).
We next addressed whether expression of DC-SIGN on this
subset of B cells was related to a state of cellular activation.
For this, we determined the proportion of B cells that
expressed CD23, another type II C-type lectin receptor that is
a low-afﬁnity Fc receptor for IgE (Fc epsilon RII) and is
associated with B cell activation and differentiation [15]. We
found that DC-SIGN and CD23 were coexpressed on 8.1 6
1.7% of B cells in normal persons (Figure S1A, T0). Indeed,
80% of DC-SIGN
þ B cells also expressed CD23 (unpublished
data). To further delineate the relationship of B cell
activation to DC-SIGN, we examined whether stimulation of
B cells with the T helper type 2 (Th2) cytokine interleukin 4
(IL-4) alone or in combination with the CD4
þT cell activation
factor CD40L could alter expression of DC-SIGN and CD23, a
procedure that mimics activation of B cells by CD4
þ T helper
cells during antigen processing [18,19]. Also, IL-4 has been
shown to up-regulate expression of DC-SIGN on monocyte-
derived DC [20], breast-milk macrophages [21], and the THP-
1 cell line [22]. Our data demonstrate that treatment of
puriﬁed B cells with a range of concentrations of either IL-4
or CD40L alone had little effect on the expression of DC-
SIGN or CD23 by 24 h (Figure 1D, top; Figure S1B, top) or 48
h (unpublished data). In contrast, treatment with a combina-
tion of different concentrations of IL-4 and CD40L had a
synergistic effect on expression of DC-SIGN and CD23 on B
cells, with the greatest increase in the number of B cells
expressing DC-SIGN being induced by stimulation with 1,000
U/ml of IL-4 and 1 lg/ml of CD40L for 24 h (Figure 1D, top
and bottom, respectively; Figure S1B, bottom). This treatment
was therefore used for stimulation of B cells in subsequent
experiments.
Cumulative data from 33 normal donors showed that
expression of DC-SIGN by puriﬁed, peripheral blood CD20
þ
B cells signiﬁcantly increased after stimulation of the cells for
24 h with IL-4 and CD40L (representative example, Figure
1B) from a mean level of 7.9 6 1.8% to 28.2 6 3.3% (p ¼
0.0001) (Figure 1C). Moreover, the mean ﬂuorescence
intensity (MFI) of DC-SIGN on the B cells increased 3-fold
after stimulation, from 10.8 6 2.4 to 30.2 6 6.6 (p , 0.005).
The DC-SIGN
þ CD23
þ B cell population also increased from
8.1 6 1.7% at 0 h to 25.7 6 3.2% at 24 h (n ¼ 33; p , 0.0002;
Figure S1A, T24), with 86% of DC-SIGN
þ cells expressing
CD23 after 24 h of stimulation (unpublished data).
To conﬁrm the increase in DC-SIGN expression in B
lymphocytes stimulated by IL-4 and CD40L, we measured the
level of DC-SIGN mRNA by real-time reverse transcriptase
PCR [23,24] in B cells stimulated with IL-4 and CD40L
compared to unstimulated B cells. B cells from ﬁve of seven
normal donors (donors 1, 2, 4, 5, and 7) had large, 6.1- to
122.4-fold increases in levels of DC-SIGN mRNA, accompa-
nied by an increase in surface expression of DC-SIGN (Table
1). B lymphocytes from the other two donors (donors 3 and 6)
had low-to-moderate, 1.1- to 2.1-fold increases in DC-SIGN
mRNA levels together with increases in surface expression of
DC-SIGN after stimulation.
We next examined whether HIV-1 infection altered the
number of B cells expressing DC-SIGN in the peripheral
blood of HIV-1–infected persons, and the capacity of their B
cells to respond to stimulation with IL-4 and CD40L. We
found that the percentage of DC-SIGN
þ B cells in the blood
of HIV-1–infected persons with chronic HIV-1 infection who
were antiretroviral therapy (ART) naive or those who had
suppressed viral infection on ART was similar to uninfected
persons (Figure 1C). However, expression of DC-SIGN was
not enhanced on B cells from the HIV-1–infected subjects on
ART in response to stimulation with IL-4 and CD40L,
whereas DC-SIGN expression was enhanced in B cells from
HIV-1–uninfected persons and ART-naive, HIV-1–infected
subjects.
Next we compared the level of expression of DC-SIGN to
other surface molecules that are known to increase during B
cell activation and that play an important role in the
interaction between B and T lymphocytes. Flow cytometry
analysis of puriﬁed, IL-4– and CD40L-stimulated B cells for
expression of DC-SIGN, CD23, the B cell signal transduction
molecule CD22, and T cell co-stimulatory molecules CD58,
CD80, and CD86 showed that there was an increase in
coexpression of all of these markers with DC-SIGN at 24 h
compared to 0 h (p , 0.005; T0 and T24, Figure 2A) or mock-
stimulated B cells at 24 h (p , 0.05; unpublished data).
Finally, we determined the expression of CD4 and the
chemokine receptors CXCR4 and CCR5 on B cells, which are
the primary receptor and coreceptors involved in HIV-1 cis
infection. Although a small subset of B cells from the blood
expressed low levels of CD4, this marker was not detectable
after 24 h (Figure 2B) or 48 h (unpublished data) of
stimulation of the B cells with IL-4 and CD40L. High levels
of expression of the CXCR4 coreceptor for HIV-1 were
evident on most B cells before and after stimulation with IL-4
and CD40L, whereas the CCR5 coreceptor was not expressed.
Taken together, these results indicate that a distinct
population of activated B lymphocytes constitutively ex-
pressed DC-SIGN in the blood of normal donors. Moreover,
there was a signiﬁcant increase in the frequency and intensity
of DC-SIGN–expressing B cells derived from HIV-1–negative
subjects and HIV-1–infected persons not on ART, which was
not observed in HIV-1–infected persons on ART, after 24 h of
stimulation with IL-4 and CD40L. Finally, the activated B cells
expressed the CXCR4 coreceptor for HIV-1, but not the
primary CD4 receptor or the CCR5 coreceptor for the virus.
B Cells Express Sufficient Levels of DC-SIGN for HIV-1 trans
Infection of T Cells
It has been shown in both DC and transfected cell lines that
surface expression of a minimum of approximately 60,000
molecules of DC-SIGN is necessary for transmission of HIV-1
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Synopsis
A cell surface molecule, DC-SIGN, is known to bind the AIDS virus,
human immunodeficiency virus 1 (HIV-1), on dendritic cells. HIV-1
can then be transferred from these dendritic cells to CD4
þ T cells, in
which the virus replicates and kills the T cells. Here, Rappocciolo and
colleagues present their findings that DC-SIGN serves a similar
function on a subset of B cells of the peripheral blood and tonsils.
Although B cells that express DC-SIGN do not replicate HIV-1, they
serve as portals for transfer and enhanced HIV-1 infection of CD4
þ T
cells, the major site of virus replication in the host. This newly
described pathway for HIV-1 infection of T cells via B cells could be
important in the pathogenesis of the virus infection.to T cells [25]. We therefore determined the level of
expression of DC-SIGN on blood-derived B cells as compared
to DC and Raji–DC-SIGN cells by antibody binding capacity
(ABC) and the number of molecules of equivalent soluble
ﬂuorochrome (MESF). The results show that IL-4– and
CD40L-stimulated B cells expressed 137,870 6 22,432 ABC
(n ¼ 6) for DC-SIGN compared to mock-stimulated B cells
(36,946 6 1,125, n¼6), DC (213,350 6 43,370 ABC; n¼6), and
Raji–DC-SIGN cells (225,750 6 19,880 ABC; n ¼ 4) (Figure
3A). A similar quantitative expression of DC-SIGN was
observed on activated B cells by MESF (Figure 3B). The
MESF and ABC histogram proﬁles for DC-SIGN on activated
B cells compared to DC and Raji–DC-SIGN cells are shown in
Figure 3C. These data support that IL-4– and CD40L-
stimulated B cells expressed a sufﬁcient number of DC-SIGN
molecules for transfer of HIV-1 to T cells.
Activated B Cells Transmit HIV-1 X4 and R5 Strains to T
Lymphocytes
Our ﬁnding that B lymphocytes expressed DC-SIGN led us
to investigate whether these cells could be exploited by HIV-1
as a means for enhanced infection of T cells, as has been
demonstrated for DC [1,26]. We ﬁrst examined whether HIV-
1 was able to bind to B cells and be transmitted to T
lymphocytes through DC-SIGN using a low concentration of
HIV-1 (multiplicity of infection [MOI] ¼ 10
 4, corresponding
to 10 pg of p24 per 10
6 cells), similar to that used in studies of
DC-SIGN–related transmission of HIV-1 from DC to T cells
[1,27]. This low amount of virus usually does not result in
efﬁcient cis infection of T cells. As displayed in Figure 4A,
when the puriﬁed IL-4– and CD40L-stimulated B cells were
incubated with X4 tropic HIV-1 (strain IIIb) and then co-
cultured with autologous CD4
þ T cells, virus replicated in the
cultures as shown by an increase from undetectable, ,1310
1
Figure 1. Expression of DC-SIGN on B Cells
(A) B cells within the PBMC population expressed DC-SIGN. PBMC were assessed for expression of CD45, CD19, and DC-SIGN by flow cytometry. Cells
coexpressing CD45 and CD19 (left) were analyzed for DC-SIGN coexpression (right). Quadrant positions were determined with the isotype controls.
(B) Increase in coexpression of DC-SIGN on CD20
þcells detected by flow cytometry in unstimulated, purified, fresh B cells (0 h; T0) and IL-4– and CD40L-
stimulated, purified B cells at 24 h (T24). Data are from a representative, healthy HIV-1–seronegative donor.
(C) DC-SIGN expression on B cells from healthy, HIV-1–seronegative donors (n ¼ 33, left), HIV-1–seropositive, ART therapy–naive subjects (n ¼ 10,
middle), and HIV-1–seropositive subjects receiving ART (n ¼ 10, right). Quadrants were positioned on the isotype controls.
(D) CD40L and IL-4 acted synergistically in inducing enhanced DC-SIGN expression in B cells by 24 h. In this representative experiment (top), purifiedB
cells were cultured in the presence of IL-4 or CD40L or a combination of the two. Untreated B cells were used as controls (NT). DC-SIGN and CD20
coexpression on activated B cells was greatest using a combination of 1,000 U/ml of IL4 and 1 lg/ml of CD40L for 24 h (bottom). Single concentrations
of 100, 500, and 2,000 U/ml of IL-4 and 0.1, 0.5, and 10 lg/ml of CD40L induced similar, low levels of DC-SIGN expression (unpublished data); various
combinations of these concentrations of IL-4 and CD40L induced less DC-SIGN expression than this combination (unpublished data).
DOI: 10.1371/journal.ppat.0020070.g001
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B Cells Transmit HIV to T Cellspg of p24 per ml at day 4, to .4310
3 pg at day 16. Puriﬁed B
cells not stimulated with IL-4 and CD40L, and loaded with
HIV-1 X4 and cultured with T cells for 24 h, were not capable
of enhancing HIV-1 infection in the co-cultures. Levels of
HIV-1 X4 remained below detection in IL-4– and CD40L-
stimulated B cells, mock-stimulated B cells, and T cells alone
(Figure 4A). This indicates that virus replication in the B–T
cell co-cultures was not a result of direct, cis infection of the T
cells or B cells by HIV-1. For these HIV-1 transmission
experiments, we used B cells obtained from magnetic bead–
puriﬁed fractions with .96% CD20
þ cells and ,1% T cells
and monocytes. However, to ensure that the observed results
were not due to contamination with other cell types, we also
found that fractions of .96% pure B cells obtained by ﬂow
cytometry sorting were able to transmit HIV-1 to T cells with
the same efﬁciency as the magnetic bead–puriﬁed B cells
(unpublished data).
Further experiments demonstrated that IL-4– and CD40L-
activated B cells loaded with three different concentrations of
HIV-1 X4 resulted in a dose response–related level of
infection in the B–T cell co-cultures (Figure 4B). Levels of
HIV-1 p24 increased from undetectable, ,1 3 10
1 pg per ml
on day 4, to  5 3 10
4 pg of p24 per ml on day 16 at the
highest input MOI (i.e., 10
 3), and .1.7310
4 and .8310
3 pg
per ml at the lower, 10
 4 and 10
 5 MOI, respectively. Virus did
not replicate at any of these input concentrations in B cells or
T cells alone (Figure 4B).
We next investigated whether expression of CD4, CXCR4,
or CCR5 by B cells was related to trans infection of T cells. As
shown in Figure 2B and in the literature [28], low numbers of
unstimulated B cells in blood express very low levels of CD4.
Moreover, expression of CD4 was down-regulated after
stimulation of the B cells with IL-4 and CD40L for 24 h
(Figure 2B). We next demonstrated that activated B cells
enhanced trans infection of CD4
þ T cells with a low MOI of
the HIV-1 R5 tropic, Ba-L strain (Figure 4C), comparable to
HIV-1 X4, even though B cells do not express CCR5 (Figure
2B) [28]. Moreover, cis infection of either unstimulated B cells
(unpublished data), stimulated B cells (Figure 4C), or T cells
(Figure 4C) with HIV-1 R5 at this low MOI did not result in
virus replication.
Taken together, our data indicate that IL-4– and CD40L-
activated B cells from HIV-1–negative persons mediated
efﬁcient trans infection of autologous CD4
þT cells with either
X4 or R5 tropic HIV-1. Furthermore, this trans infection was
not related to CD4, CXCR4, or CCR5 expression on the B
cells. The fact that these were puriﬁed B cells from HIV-1–
negative persons indicates that HIV-1 immune complexes
and other types of cells were not involved in this process. It
should also be noted that we did not include the lectin
polybrene, a commonly used, receptor-independent en-
hancer of HIV-1 infection [29], in any of the cultures.
B Cell–Mediated Transmission of HIV-1 to T Cells Is
Dependent on Expression of DC-SIGN by the B Cells
Based on the above results, we reasoned that DC-SIGN
could be involved in B cell–mediated trans infection of T cells.
To address this hypothesis, we ﬁrst examined the relationship
between DC-SIGN expression on puriﬁed B cells and uptake
of HIV-1. Virus was expressed together with DC-SIGN in
activated B cells after 2 h of exposure of the cells to virus as
detected by immunoﬂuorescent microscopy (Figure 5A).
Quantitative immunoﬂuorescence analysis by ﬂow cytometry
showed that 80% of B cells expressing HIV-1 p24 were DC-
SIGN
þ (Figure 5B). Our results also demonstrated that there
was no alteration of DC-SIGN expression by B cells or DC
loaded with HIV-1, although there was minimal down-
regulation of DC-SIGN expression on HIV-1–infected, Raji–
DC-SIGN cells by 24 h, using an MOI of 10
 4 (unpublished
data) or 10
 3 (Figure 5C). This is in contrast to our recent
Table 1. Real-Time RT-PCR Measurement of DC-SIGN mRNA Levels in B cells of Seven Healthy, HIV-1 Seronegative Donors
Donor Time CT
a Fold Change (2
 DDCT) MFI
b % CD209
þ/CD20
þc
1T 0 .40.0 1 16.1 12
T24 33.6 122.4 41.8 41.5
2T 0 .40.0 1 10.0 1.1
T24 35.1 21.6 34.0 20
3T 0 .40.0 1 20.7 5.5
T24 39.3 2.1 33.7 11.5
4T 0 .40.0 1 15.2 8.2
T24 34.0 62.3 58.4 55.0
5T 0 .40.0 1 4.3 0.3
T24 38.2 6 4.3 5.2
6T 0 .40.0 1 1.3 4.1
T24 38.5 1.1 16.5 13.0
7T 0 .40.0 1 1.0 1.9
T24 35.7 10.2 11.3 10.3
DC 31.3 .5,792 245 95%
K562 cells .40 1 3.0 0% CD209
þ
K562–DC-SIGN cells
d 26.4 .17,560 3,377 88.8% CD209
þ
aA maximal measure of DC-SIGN mRNA expression of CT ¼ 40 was used for all calculations using K562 cells and CD19
þ (CD19
pos) B cells (time 0 h ¼ T0) as the appropriate calibrators.
Therefore, the fold-increase measurements at time 24 h (T24) are minimal estimates.
bMFI of DC-SIGN on B cells analyzed by flow cytometry.
cPercent of DC-SIGN
þ/CD20
þ B cells as calculated above the background levels given by the isotype controls.
dK562–DC-SIGN cells are K562 cells stably transfected with a plasmid encoding DC-SIGN.
DOI: 10.1371/journal.ppat.0020070.t001
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B Cells Transmit HIV to T Cellsﬁndings that human herpesvirus 8 infects DC and macro-
phages via DC-SIGN and results in loss of surface expression
of DC-SIGN [30]. Thus, after exposure of IL-4– and CD40L-
activated B cells to HIV-1, the virus is associated with DC-
SIGN
þbut not DC-SIGN
 B cells, and there is no alteration in
DC-SIGN expression in these cells as detected by ﬂow
cytometry.
We next determined the role of DC-SIGN on B cells in trans
infection of T cells by treating IL-4– and CD40L-activated B
cells with anti–DC-SIGN mAb or two nonspeciﬁc IgG as
controls, one with the same isotype as the anti–DC-SIGN
mAb (IgG2b) and the other of a different isotype (IgG1), prior
to incubation with HIV-1 X4 or HIV-1 R5 and co-culture with
T cells. The results show that pretreatment of B cells with
anti–DC-SIGN mAb inhibited HIV-1 X4 and R5 replication in
the B–T cell co-cultures, whereas pretreatment with the
control IgG had no effect (Figures 6A and 6B). Also,
inhibition of HIV-1 transmission by anti–DC-SIGN mAb
was dose-dependent (Figure 6C). Because T cells do not
express DC-SIGN [17], this virus-inhibitory effect was related
to blocking of DC-SIGN on the activated B cells. These results
indicate that HIV-1 X4 and R5 strains can be associated with
B cells via DC-SIGN and that this leads to trans infection of T
cells.
Although activated B cells did not express the primary CD4
receptor or the CCR5 coreceptor necessary for conventional
infection by HIV-1 R5 (Figure 2B), they did express high levels
of the CXCR4 coreceptor for HIV-1 (Figure 2B) [28]. Even
though this is an inefﬁcient receptor for HIV-1 infection in
the absence of CD4 [31], we examined whether HIV-1 X4 trans
infection of T cells was related to CXCR4 expression on the B
cells. We treated activated B cells with anti-CXCR4 mAb or an
IgG control, and showed that this did not inhibit HIV-1 X4
trans infection of T cells, whereas trans infection was blocked
by pretreatment of the B cells with anti–DC-SIGN mAb
(Figure 6D).
Taken together, these results show that DC-SIGN expres-
sion on puriﬁed, IL-4– and CD40L-activated, peripheral
Figure 2. Coexpression of DC-SIGN and Markers of Activation on B Cells
Expression of CD20, CD22, CD23, CD58, CD80, and CD86 in purified, unstimulated ([A] time 0 h; T0) and IL-4– and CD40L-stimulated ([B] time 24 h; T24)
B cells. The quadrants were set on the isotype controls. Expression of CD4, CXCR4, and CCR5 is shown for unstimulated (full histograms) and stimulated
(24 h; red profile histograms), purified B lymphocytes. Isotype controls are indicated by gray lines. Data are from a single experiment representative of
five independent experiments.
DOI: 10.1371/journal.ppat.0020070.g002
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B Cells Transmit HIV to T Cellsblood B cells is directly related to trans infection of T cells. We
hypothesized that this process could occur during B–T cell
interactions in lymphatic tissues. In support of this, we found
that DC-SIGN was expressed by 26.4 6 6% (n ¼ 5) of single-
cell suspensions of puriﬁed tonsil B cells (representative
example, T0, Figure 7A). In contrast to blood B cells, there
was little coexpression of CD23 by freshly puriﬁed, tonsil B
cells, but comparable up-regulation of CD23 and coexpres-
sion with DC-SIGN after 24-h stimulation with IL-4 and
CD40L (T24, Figure 7A). Importantly, trans infection of T cells
was mediated by the stimulated tonsil B cells, as demon-
strated by an increase in p24 levels from ,1 3 10
1 pg per ml
at day 4 to .3 3 10
3 pg per ml at days 8 to12 in the B–T cell
co-cultures (Figure 7B). Over 90% of this virus replication
was blocked by pretreatment of the B cells with anti–DC-
SIGN mAb. Thus, both DC-SIGN expressing blood and
lymphatic tissue B cells can mediate efﬁcient trans infection
of T cells.
HIV-1 Is Internalized in Activated B Cells
HIV-1 is predominantly found within cytoplasmic vacuoles
in DC after binding to DC-SIGN [3]. This could relate to
different pathways of HIV-1 that are required for subsequent
trans infection of T cells. We therefore conducted a series of
Figure 3. Quantitation of DC-SIGN Expression on B Cells
ABC and MESF (panels [A] and [B], respectively) of unstimulated (resting [rB]) and activated (aB) B cells and DC from six donors, and four independent
samplings of Raji–DC-SIGN cells, were determined as described in Materials and Methods. p , 0.008 for ABC and p , 0.001 for MESF comparing rB to aB
cells; p ¼ NS comparing aB cells to DC or Raji–DC-SIGN cells. The red lines indicate the mean values for ABC and MESF. In panel (C), the histogram
profiles of expression of DC-SIGN on activated B cells and DC from one representative donor are shown, as well as the profile of expression of DC-SIGN
on Raji–DC-SIGN cells for comparison (full histograms: DC-SIGN positive cells, black line overlay histograms: isotype control).
DOI: 10.1371/journal.ppat.0020070.g003
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B Cells Transmit HIV to T Cellsexperiments to assess whether HIV-1 was internalized by B
cells. We ﬁrst examined the physical association of HIV-1
with puriﬁed, activated B cells and DC by electron micro-
scopy. As expected, no viral particles were observed in
activated B cells not loaded with HIV-1 (Figure 8A). Activated
B cells incubated with HIV-1 for 1 h at 4 8C had viral particles
bound only to their outer surface (Figure 8B). However,
activated B cells exposed to HIV-1 for 2 h at 37 8C had viral
particles internalized in vacuoles of the cell cytoplasm (Figure
8C), with no intracellular virus apparent outside of vacuoles.
Both intact viral particles and possible degraded virions were
present in the vacuoles, similar to those observed after
internalization of HIV-1 in DC (Figure 8D; [3]).
To prove further that HIV-1 particles were localized inside
B lymphocytes and not merely bound to their surface, we
incubated activated B cells with AT-2 inactivated HIV-1 X4
particles for 2 h at 37 8C to allow internalization, and then
treated the cells with trypsin to cleave virions still bound on
the cell surface. The culture medium was removed, and the
cells were washed and lysed. HIV-1 p24 contained in the wash
supernatants and cell lysates was measured by enzyme-linked
immunosorbent assay (ELISA). Under these conditions,
essentially all of the p24 was found in the whole cell lysate,
as very little was detected in the cell culture supernatants
collected after the trypsin treatment (Figure 8E). To prove
that internalized virus and not surface-bound virus was
transferred from B cells to the T cells, we next performed a
protease protection transmission assay. Cells were loaded
with HIV-1 R5 at 4 8C (wet ice) for 1 h, washed, and then
shifted to 37 8C for the times indicated prior to treatment
with trypsin or medium (mock treatment). As shown in Figure
8F, very brief proteolysis of the B cells that had been exposed
to HIV-1 at 4 8C to inhibit virus entry and then shifted to 37
8C (i.e., 0 min incubation) prevented transmission of HIV-1 to
the T cells. In contrast, proteolysis of the HIV-1–loaded B
cells after shifting to 37 8C for 30 min did not prevent trans
infection of the T cells. These data support that HIV-1 was
internalized by the activated B cells prior to transmission to T
cells.
Finally, we examined the ability of HIV-1 to remain
infectious in B cells over time, as has been shown for HIV-1
infection of DC [32]. For this, we exposed activated B cells to
infectious X4 or R5 strains of HIV-1 for 2 h at 37 8C, and then
either mixed them immediately with T cells or kept them at
37 8C for 2 d before mixing with T cells. As shown in Figure
9A and 9B, B cells that were loaded with HIV-1 and cultured
alone for 2 d could still transmit virus to T cells, although at a
lower efﬁciency then when T cells were added immediately to
the HIV-1–exposed B cells. Taken together, these results
indicate that HIV-1 was captured and internalized in
activated B cells, where it remained infectious for T cells
for at least 2 d.
Discussion
Our results demonstrate that activated B lymphocytes
derived from peripheral blood and lymphatic tissue express
DC-SIGN, and that these cells mediate HIV-1 trans infection
of T lymphocytes. Evidence for trans infection was an increase
of HIV-1 p24 from undetectable levels (,1 3 10
1 pg/ml) to
.10
3–10
4 pg/ml after 12–16 d of co-culture of the activated B
cells with autologous CD4
þT cells. The trans infection was not
due to direct cis infection of the B cells, as virus replication
was not detectable in B cells alone after exposure to HIV-1.
Likewise, there was little or no detectable replication of HIV-
1 after direct infection of T cells alone with the low input of
HIV-1 used in our experiments. Expression of DC-SIGN by
Figure 4. Activated B Cells Transmit HIV-1 X4 and R5 to T Cells
(A) Levels of HIV-1 p24 in B cells stimulated with IL-4 and CD40L
(activated B cells [aB]) or mock stimulated (resting B cells [rB]) for 24 h
and loaded with 10
 4 MOI of HIV-1 X4 (IIIb) for 2 h at 37 8C, then
extensively washed in cold medium and incubated with purified,
autologous CD4
þ T cells (T). B cells and T cells directly loaded with
HIV-1 served as controls.
(B) Dose response of HIV-1 trans infection shown by levels of p24 in
cultures of autologous T cells (T) mixed with activated B cells (B) that
were loaded with 10
 5,1 0
 4,o r1 0
 3 MOI of HIV-1 X4 (IIIb). The results
shown are representative of three independent experiments with B and
T cells from different donors.
(C) Activated B cells (B) transmitted both HIV-1 X4 (IIIb) and R5 (Ba-L)
strains to autologous T cells (T) as shown by increases in levels of p24. T
cells and B cells were separately cultured with either strain of virus as
controls. Data are represented as the means of triplicates 6 SE, and are
from single experiments representative of five or more independent
experiments.
DOI: 10.1371/journal.ppat.0020070.g004
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B Cells Transmit HIV to T Cellsthe B cells was associated with this enhanced HIV-1 infection
of CD4
þ T cells in trans. That is, treatment with IL-4 and
CD40L, which are mediators of B cell activation by CD4
þ T
cells [19], enhanced DC-SIGN expression on the B cells. A
total of 80% of the HIV-1–infected B cells were DC-SIGN
þ by
ﬂow cytometry. This was supported by immunoﬂuorescence
microscopy analysis showing that DC-SIGN and HIV-1 were
coexpressed in the B cell cytoplasm. Association of virus with
a small portion of non-DC-SIGN–expressing B cells could be
related to expression of other C-type lectin receptors by B
cells that bind gp120 [16]. Most importantly, DC-SIGN
expression by the B cells was required for trans infection of
CD4
þ T cells with both X4 and R5 tropic strains of HIV-1, as
we could block essentially all of the trans infection by
pretreating the B cells with mAb speciﬁc for DC-SIGN.
In further support of a central role for DC-SIGN on B cells
in HIV-1 trans infection, we found that the number of DC-
SIGN molecules expressed on activated B cells was similar to
that known to be sufﬁcient to sustain capture of HIV-1 and
trans infection of T cells by DC [25]. Notably, the mechanism
of trans infection of T cells by B cells did not involve HIV-1
infection of B cells by the conventional, CD4-CXCR4/CCR5
pathway. This was supported by the fact that B cells expressed
little or no CD4 and did not express CCR5. Moreover,
although B cells expressed high levels of CXCR4, treatment
with anti-CXCR4 mAb prior to virus binding to the B cells did
not inhibit trans infection of the T cells. Thus, although other
C-type lectin receptors are expressed on B cells and can bind
gp120 [16], our results support a requirement for DC-SIGN in
B cell–mediated, trans infection of T cells.
HIV-1 was internalized by B cells as determined by
resistance of B cell–associated virus to treatment with trypsin,
and predominance of virus particles in cytoplasmic vacuoles
of B cells after binding to DC-SIGN. Both intact and
apparently degraded particles were present within the
vacuoles, similar to HIV-1 internalization in DC via DC-SIGN
[3]. Internalized and not extracellularly bound virus resulted
in trans infection of T cells, which was demonstrated by lack
of effect of trypsin treatment of HIV-1–loaded B cells on
their ability to mediate trans infection. These results suggest a
role for internalization of HIV-1 by B cells that is similar to
that of DC in trans infection of T cells [33]. We further
observed that virus was maintained for at least 2 d in an
infectious form in B cells, comparable to its association with
DC [32]. It is not clear how this virus infectivity persists.
Recent studies indicate that most of the captured virions are
destroyed in DC-SIGN–expressing DC and B cell lines
engineered to express DC-SIGN [3,34]. However, a portion
Figure 5. Expression of DC-SIGN and HIV-1 in B Cells
(A) Immunofluorescent microscopy showing coexpression of DC-SIGN and HIV-1 in IL-4 and CD40L purified, activated B cells after 2 h of exposure to
HIV-1 X4 (MN) at 37 8C. B cells not exposed to HIV-1 were used as controls; these included a subset that expressed DC-SIGN and were negative for HIV-1
(unpublished data). (6003 magnification) Green indicates DC-SIGN, red indicates p24, and blue indicates DAPI.
(B) Flow cytometry histograms showing coexpression of DC-SIGN and HIV-1 in IL-4 and CD40L purified, activated B cells after 2 h of exposure to HIV-1
X4 (MN) at 37 8C.
(C) HIV-1 R5 (Ba-L) had no effect on expression of DC-SIGN by purified, activated B cells (left) or DC (middle), and minimally inhibited DC-SIGN
expression in Raji–DC-SIGN cells (right) after 24 h incubation with the virus. Full histogram represents uninfected B cells; purple overlay histogram
represents HIV-1–infected cells; and black overlay histogram represents isotype controls. Data are from single experiments representative of five
independent experiments.
DOI: 10.1371/journal.ppat.0020070.g005
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B Cells Transmit HIV to T Cellsof the input virus can rapidly trans infect T cells [3,35]. In
contrast, the longer term, persistent infectivity of DC-SIGN–
expressing DC and B cell lines has been related to low levels
of de novo HIV-1 replication [3,35]. It is possible that very
low, subdetectable levels of HIV-1 replication occurred in our
IL-4– and CD40L-stimulated B cells, and resulted in
persistence of infectious virus involved in trans infection of
T cells. Further work is in progress to delineate the
mechanisms by which DC-SIGN–expressing B cells lead to
HIV-1 trans infection of T cells.
The DC-SIGN–mediated, B-to-T cell trans infection path-
way appears to be distinct from previously described B–T cell
infectious processes. That is, it has been reported that
transmission of HIV-1 from B cells to T cells involves virus
trapped in immune complexes on the surface of the B cells
[6–10]. This is not involved in our system, since in our studies,
HIV-1 trans infection of T cells was mediated by B cells from
normal, HIV-1 antibody–negative persons. Finally, in contrast
to Swingler et al. [11], where nef-induced soluble factors
released by infected macrophages work together with B cells
to lead to trans infection of T cells, we observed trans infection
of T cells by puriﬁed, DC-SIGN
þ B cells in the absence of
macrophages.
Notably, we found that approximately 8% of B cells in the
blood of normal donors expressed DC-SIGN. Stimulation for
24 h with IL-4 and CD40L resulted in an increase in the
number of B cells expressing DC-SIGN (i.e., 28%) and the
level of DC-SIGN expression on the B cells. Approximately
80% of the DC-SIGN
þB cells in blood also expressed the type
II C-type lectin receptor and B cell activation marker, CD23,
which increased to 86% after stimulation in vitro with IL-4
and CD40L. Activation of these stimulated, DC-SIGN
þ B cells
was conﬁrmed by elevated levels of T cell coreceptors CD58,
CD80, and CD86, as well as increases in coexpression of the B
Figure 6. B Cell–Mediated Transmission of HIV X4 and R5 to T Cells Is Blocked by Anti–DC-SIGN mAb
(A) and (B) HIV-1 p24 levels in cultures of activated B cells that were treated with anti–DC-SIGN mAb, incubated with either HIV-1 X4 (IIIb) (Figure 6A) or
R5 (Ba-L) (Figure 6B) for 2 h at 37 8C, washed and co-cultured with autologous T cells. B and T cells cultured alone with each virus were used as controls.
(C) HIV-1 p24 levels in cultures of activated B cells that were incubated with decreasing amounts of anti–DC-SIGN mAb prior to exposure to HIV-1 R5
(Ba-L) and culture with autologous T cells for 8 d. Treatment with mouse IgG or an unrelated mAb (anti-CD11a) had no effect on HIV-1 R5 (Ba-L) trans
infection.
(D) HIV-1 p24 levels in cultures of activated B cells incubated with anti–DC-SIGN mAb or anti-CXCR4 mAb, washed, loaded with HIV-1 X4 (IIIb), and co-
cultured with autologous T cells for 12 d.
Data are represented as mean of triplicates 6 SE. Data are from single experiments representative of eight independent experiments.
DOI: 10.1371/journal.ppat.0020070.g006
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B Cells Transmit HIV to T Cellscell signal transduction molecule CD22. Expression of DC-
SIGN was not restricted to blood B cells, as we found that
approximately 26% of tonsil B cells constitutively expressed
DC-SIGN, and that this increased to 39% after stimulation of
the cells with IL-4 and CD40L. Interestingly, our study
showed that few B cells directly isolated from the tonsils
expressed CD23, but that this number increased after
stimulation with IL-4 and CD40L. Expression of CD23 on
some but not all DC-SIGN
þ B cells could be related to
differential expression of CD23 by B cells in distinct areas of
tonsils [36], and a pronounced cleavage and shedding of
soluble CD23 by activated B cells [37].
Of interest is that there was a comparable number of DC-
SIGN–expressing B cells in the blood of uninfected persons as
in those with chronic HIV-1 infection who were treatment
naive or receiving ART. In support of these ﬁndings, although
B cells can harbor HIV-1 in blood [6], we found that HIV-1
did not kill B cells or inhibit DC-SIGN expression within 24–
Figure 7. DC-SIGN–Expressing Tonsil B Cells Mediate trans Infection of T Cells
(A) Expression of CD20 and DC-SIGN or CD23 and DC-SIGN in fresh (time 0 h; T0) and IL-4– and CD40L-activated (time 24 h; T24) B cells derived from
tonsils. Data are from one experiment representative of five independent experiments.
(B) Levels of HIV-1 p24 in co-cultures of B and T cells derived from tonsils. B cells were stimulated with IL-4 and CD40L for 24 h, treated with anti–DC-
SIGN mAb or mouse Ig (20 lg/ml) or left untreated, and loaded with 10
 4 MOI of HIV-1 R5 (Ba-L) for 2 h at 37 8C, then extensively washed in cold
medium and incubated with purified, autologous CD4
þT cells (T). B cells and T cells directly loaded with HIV-1 served as controls. Amount of HIV-1 p24
in the cell culture supernatants was determined by ELISA. Data are from one experiment representative of two independent experiments.
DOI: 10.1371/journal.ppat.0020070.g007
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B Cells Transmit HIV to T Cells48 h of exposure to virus in vitro. Our observation that IL-4
and CD40L stimulation of B cells from persons receiving ART
failed to enhance expression of DC-SIGN suggests a negative
effect of ART on this process. This could be related to the
reported inhibitory effect of protease inhibitors, which are
common components of ART, on expression of DC-SIGN
[38], and requires further study.
Expression of DC-SIGN on B cells suggests that it is
operative in their normal function. This type II C-type lectin
receptor could be involved in B cell trafﬁcking and antigen
presentation to T cells, similar to its function in DC [39].
Indeed, high levels of expression of DC-SIGN were induced in
B cells by a combination of T cell factors IL-4 and CD40L and
not by either alone. These results support the concept that
DC-SIGN is involved in the interaction of activated B and T
cells during antigen processing and presentation.
Our data indicate that DC-SIGN–expressing B cells could
become vehicles for HIV-1 infection of T cells during their
cognate interactions in the lymphatics. High concentrations
of HIV-1 have been found associated with B cells and CD4
þ T
cells in lymph nodes [40], where B cells are activated and
proliferate through cytokine and CD40L-CD40 interactions
[41]. This has been related to virus-containing immune
complexes on the surface of B cells that could lead to
infection of CD4
þ T cells during ‘‘cross talk’’ in the micro-
environment of lymphoid tissues. The presence of a large
amount of unspliced simian immunodeﬁciency virus RNA in
B cell–rich areas of lymphoid tissues [42], is also consistent
with virions being associated with B cells and follicular DC in
germinal centers. B cells have therefore been proposed as an
important, lymphatic reservoir in the pathogenesis of HIV-1
[28]. Our results suggest that B cells play a previously
unrecognized role in replication of HIV-1 in T cells and viral
pathogenesis through a DC-SIGN–dependent mechanism.
Materials and Methods
Donors. PBMC were obtained from healthy, HIV-1–seronegative (n
¼ 33) and HIV-1–seropositive (n ¼ 20) adult volunteers and subjects
enrolled in the Multicenter AIDS Cohort Study. Informed consent
was obtained following institutional guidelines. ART-naive, HIV-1–
seropositive subjects (n ¼ 10) had mean (6 SE) of 658 6 124 CD4
þ T
cells per ml of blood, and HIV-1 RNA loads of 6,410 6 3,701 copies
per ml of plasma; HIV-1–seropositive subjects on ART (n ¼ 10) had
Figure 8. HIV-1 Is Internalized in B Cells
(A–D) Transmission electron microscopy of HIV-1–loaded, activated B cells and DC. Activated B cells were left untreated (panel A) or loaded with AT-2–
inactivated HIV-1 X4 (MN) for 1 h at 4 8C (panel B) or at 37 8C for 2 h (panel C). Immature DC (panel D) that were loaded with the same preparation of
HIV-1 and incubated at 37 8C for 2 h were used as controls. Arrows indicate viral particles that have been internalized in cytoplasmic vesicles.
(E) HIV-1 p24 levels in post-trypsin treatment supernatants (sup) and cell pellets of activated B cells (lys) that had been incubated with AT-2–inactivated
HIV-1 X4 (MN) or HIV-1 R5 (Ba-L) for 2 h at 37 8C, and then incubated with 0.25% trypsin solution for 10 min at 37 8C. Controls included activated B cells
without virus, which were negative for p24 (unpublished data).
(F) Activated B cells were incubated with HIV-1 R5 (Ba-L) on wet ice, then washed and shifted at 37 8C for the times indicated. Cells were then treated
with trypsin or mock treated and added to T cells. Supernatants were collected every 4 d and tested for p24. Data are from single experiments
representative of three independent experiments.
DOI: 10.1371/journal.ppat.0020070.g008
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B Cells Transmit HIV to T CellsCD4
þ T cell counts of 939 6 82 and viral RNA loads of 66 6 20.
Human tonsils were obtained from patients (n ¼ 5) undergoing
therapeutic surgery, in accordance with institutional guidelines.
Preparation of B and T cells. PBMC were isolated by Ficoll-
Hypaque density gradient separation and used immediately for
surface phenotype staining or further puriﬁcation. For B cell
puriﬁcation, monocytes were depleted with two rounds of anti-
CD14 mAb-coated immunomagnetic microbeads (Miltenyi) accord-
ing to the manufacturer’s instructions. B cells (CD19
þcells) were then
isolated from the CD14
  cell fraction by incubation with anti-CD19
mAb-coated, magnetic microbeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany). The purity of the fractionated B cells was 96.4%
60.4 (mean 6 SE; n ¼ 33) as determined by staining with anti-CD20
mAb, with ,1% CD14
þ and CD3
þ cells. The immunomagnetic bead
puriﬁcation procedure did not alter expression of DC-SIGN or CD23
(unpublished data). Autologous CD4
þ T cells were obtained from the
remaining CD14
  CD19
  fraction by CD4
þ cell puriﬁcation using
anti-CD4 mAb-coated microbeads (Miltenyi). Activated B cells were
generated by culture of CD19
þ cells in RPMI 1640 medium
supplemented with 10% heat-inactivated FCS, 1,000 U/ml of rhIL-4
(R & D Systems, Minneapolis, Minnesota, United States), and 1 ug/ml
of soluble trimeric CD40 L (Amgen, Thousand Oaks, California,
United States). CD4
þ T lymphocytes were cultured in RPMI1640
medium supplemented with 20% FCS and phytohemagglutinin
(PHA) and IL-2, as described [43].
Tonsils were immediately transferred to the laboratory in cold PBS
supplemented with penicillin (100 U/ml), streptomycin (100 lg/ml),
gentamicin (5 lg/ml), ampothericin B (0.5 lg/m), and 5% FCS. The
tissues were cut into fragments and pushed through a stainless steel
sieve with a 250-lm mesh, using the ﬂat end of a plastic syringe
plunger, to remove the connective capsula. Lymphocytes from the
collected cell suspension were isolated by Ficoll-Hypaque density
gradient centrifugation. The cells collected at the interface were
stained with anti-CD20, anti-CD3, and anti-CD14 mAb to determine
the relative percentage of B and T lymphocytes, and were shown to
contain 60%–70% B lymphocytes, 30%–40% T lymphocytes, and 1 %
or less monocytes. B and T cells were puriﬁed by immunomagnetic
bead separation and activated as described above.
Preparation of DC. DC were generated from CD14
þ cells as
described [44]. Brieﬂy, CD14
þ cells were enriched from PBMC with
anti-CD14 mAb magnetic beads (.95% lineage negative, HLA DR
þ
cells) and cultured for 5 d in the presence of 1,000 U/ml of rhIL4 and
rGM-CSF.
Antibodies. The following mAbs were used in this study: anti–DC-
SIGN (CD209) (clone 120507; R & D Systems); anti-CD4, anti-CD14,
anti-CD19, anti-CD20, anti-CD22, anti-CD45, anti-CD58, anti-CD80,
anti-CD86, anti-CXCR4, and CCR5 (BD Pharmingen, San Diego,
California, United States); anti-CD23 (Caltag Laboratories, Burlin-
game, California, United States); anti–HIV-1 p24 (KC57; Beckman-
Coulter, Fullerton, California, United States). These mAbs were used
either unlabeled or conjugated with FITC, PE, PE-Cy5, or PE-Cy7 as
indicated below. Appropriate isotype-matched controls were used for
background staining evaluation. For the virus receptor blocking
experiments, we used sodium azide–free, low-endotoxin, puriﬁed,
anti–DC-SIGN clone 120507 mAb and mouse IgG of the relevant
isotype (Becton Dickinson, Palo Alto, California, United States)
reconstituted in sterile PBS.
Flow cytometry and quantiﬁcation of DC-SIGN expression.
Expression of cell surface molecules was examined by ﬂow cytometry
with a Beckman Coulter XL ﬂow cytometer. Cells were incubated
with the desired antibodies or isotype controls for 30 min at 4 8Ci n
buffer consisting of PBS supplemented with 0.1% FCS and 0.1%
NaN3. After extensive washing with the buffer, the cells were
resuspended in 1% paraformaldehyde in PBS for ﬂow cytometric
analysis. HIV-1 intracellular p24 was identify using PE-labeled KC57
anti–HIV-1 Gag mAb, following cell permeabilization using Permi-
ﬂow (Invirion Diagnostics, Oak Brook, Illinois, United States)
according to manufacturer’s instructions. Results were expressed
either as percent positive cells above the isotype control threshold or
as MFI above the isotype controls.
For quantiﬁcation of DC-SIGN expression on DC, Raji–DC-SIGN
cells, and activated B cells, we used the Quantum Simply Cellular kit
(Bangs Laboratories, Fishers, Indiana, United States) according to the
manufacturer’s instructions. Quantiﬁcation was performed by con-
verting the geometric mean channel ﬂuorescence (GMCF) into ABC.
The kit contains ﬁve microbeads of uniform size coated with different
amounts of goat anti–mouse IgG (Fc-speciﬁc) on their surface that
have different abilities to bind mouse antibodies (ranging from 0 to
about 250,000 molecules). Both beads and cells were labeled with
saturating amounts of FITC-conjugated, anti–DC-SIGN mAb, pro-
cessed, and analyzed by ﬂow cytometry under identical conditions. A
calibrating curve was derived from the bead samples using QuickCal
(Bangs Laboratories). The GMCF of the samples was converted to
ABC per cell by comparison with the regression curve generated with
the beads. Samples were also evaluated for ﬂuorescence intensity as
expressed by MESF units, using the Quantum MESF kit (Bangs
Laboratories). The kit consists of ﬁve bead populations having
different levels of FITC ﬂuorescence intensity. As described above, a
regression curve was generated by plotting the GMCF of the beads
against their known MESF using QuickCal. The MESF of the cell
samples was then determined as described above for ABC.
Real-time RT-PCR measurement of DC-SIGN mRNA. Total RNA
was extracted from cells using Trizol (Invitrogen Life Sciences,
Carlsbad, California, United States) according to the manufacturer’s
instructions, DNAse-treated (Ambion, Austin, Texas, United States)
and afﬁnity column puriﬁed (RNAeasy, Qiagen, Valencia, California,
Figure 9. HIV-1 Is Maintained in an Infectious Form by B Cells
Activated B cells were loaded with HIV-1 X4 (IIIb) or HIV-1 R5 (Ba-L) for 2 h at 37 8C, extensively washed and then either cultured immediately with
autologous T cells (panel A) or incubated for 2 d prior to adding autologous T cells (panel B). B cells and T cells directly loaded with HIV-1 served as
controls.
DOI: 10.1371/journal.ppat.0020070.g009
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B Cells Transmit HIV to T CellsUnited States). The sequences of the primers and probe for Taqman
ampliﬁcation and detection of DC-SIGN mRNA were kindly provided
by B. Lee (University of California, Los Angeles) and were DC-
SIGN.F1, 59-GCTGAGAGGCCTTGGATTCC-39;D C - S I G N . R 1 ,5 9-
AGAGCGTGAAGGAGAGGAGTTG-39; and DC-SIGN.probe, 59-
6FAM-ACCATGGCCAAGACACCCTGCTA -MGB-39. The compara-
tive threshold cycle (Ct) method [23,24] was used to determine
relative mRNA expression levels. The primer and probe set for b-
glucoronidase (b-GUS) (Applied Biosystems, Foster City, California,
United States) was used as the endogenous control. Across all
samples, mean b-GUS Ct values were 29 6 1 (unpublished data).
cDNA synthesis with 400-ng input RNA was performed in duplicate
with Superscript II reverse transcriptase (Invitrogen) and random
hexamers as described [24], in parallel with control reactions lacking
RT. Ampliﬁcation and detection for 40 cycles was performed on a
Prism 7000 Sequence Detection System (Applied Biosystems). The
fold-changes in DC-SIGN mRNA expression were calculated relative
to appropriate calibrator samples, including untransfected K562 cells
and unstimulated CD19
þ B cells.
Virus. HIV-1 IIIb (X4 tropic virus) and HIV-Ba-L (R5 tropic virus)
were propagated in PHA- and IL-2–activated, normal donor PBMC
and puriﬁed as described [43]. Virus titers were determined as pg/ml
by p24 ELISA (DuPont, Wilmington, Delaware, United States), with a
lower limit of 1310
1 pg/ml and upper limit of   5310
4 pg/ml. AT-2–
inactivated HIV-1 MN (CL.4/SUPT1; X4 tropic), and ADA (M/SUPT1-
CCR5 CL.30; R5 tropic) were a gift from J. D. Lifson, National Cancer
Institute, Frederick, Maryland.
HIV-1 infection and transmission assay. Puriﬁed,IL-4–andCD40L-
stimulated B lymphocytes (1 3 10
6) were incubated with different
amounts of HIV-1 IIIb or HIV-1 Ba-L, i.e., 10
 3,1 0
 4,o r1 0
 5 MOI at 37
8C for 2 h. The MOI was based on tissue culture infectious dose 50%
determined with susceptible CD8
 , PHA-stimulated human lympho-
cytes and conﬁrmed by spectrophotometric analysis of 10-fold serial
dilutionsonTZM-blindicatorcellline.Unlessotherwisespeciﬁed,cell-
free supernatants were taken at various time intervals for titration of
virus by p24 ELISA. No difference was observed in viability of mock-
treated and HIV-1–treated B cells as measured by trypan blue dye
exclusion.Insomeexperiments,stimulatedBcellswereincubatedwith
anti–DC-SIGN mAb (clone 120507) or CD11a/LFA-1 (clone HI111, BD
Pharmingen) or mouse IgG (R & D Systems) for 30 min at 4 8C prior to
incubation with virus. The speciﬁcity of anti–DC-SIGN mAb clone
120507 was conﬁrmed by binding to DC-SIGN–transfected K-562 cells
and lack of binding to K562 cells transfected with the DC-SIGN–
related, type II C-type lectin, DC-SIGNR [30] .
Loading of DC and activated B cells with HIV-1 for electron
microscopy. A total of 1 3 10
6 DC or puriﬁed, activated B cells were
incubated in a 1.5-ml Eppendorf tube with AT-2 HIV-1 (3 ng of p24
Ag /10
6 cells) in a total volume of 100 lla t3 78C for up to 2 h. After
the incubation, cells were extensively washed in cold medium using a
refrigerated microfuge, and the cell pellets were ﬁxed in PBS with
2.5% glutaraldehyde for 1 h. Pellets were washed three times in PBS
and then post-ﬁxed in 1% aqueous osmium tetroxide supplemented
with 1% K3Fe(CN)6 for 1 h. Pellets were then washed three times in
PBS and then dehydrated through a series of 30%–100% ethanol,
100% propylene oxide, and then inﬁltrated with 1:1 mixture of
propylene oxide–Polybed 812 epoxy resin (Polysciences, Warrington,
Pennsylvania, United States) for 1 h. After several changes of 100%
resin over 24 h, the pellet was embedded in a ﬁnal change of resin,
cured at 37 8C overnight, followed by additional hardening at 65 8C
for two more days. Ultrathin (70 nm) sections were collected onto
200-mesh copper grids, stained with 2% uranyl acetate in 50%
methanol for 10 min, followed by 1% lead citrate for 7 min. Sections
were viewed using a JEM 1210 electron microscope (JEOL, Peabody,
Massachusetts, United States).
Immunoﬂuorescence microscopy. Puriﬁed, activated B cells loaded
with AT-2 HIV-1 MN were spotted on poly-L-lysine–coated slides,
ﬁxed with 4% paraformaldehyde for 20 min, and then permeabilized
with buffer (0.5% BSA, 0.1% saponin, 0.1%NaN3) for 20 min at room
temperature. Cells were stained with FITC-conjugated, anti–DC-
SIGN mAb and PE-labeled anti–HIV-1 p24 mAb. To avoid non-
speciﬁc binding of IgG, all incubations and dilutions of reagents were
done in Super-Block blocking buffer (Pierce Biotechnology, Rock-
ford, Illinois, United States). Controls included activated B cells not
exposed to HIV-1.
Supporting Information
Figure S1. CD40L and IL-4 Act Synergistically in Inducing Enhanced
DC-SIGN and CD23 Expression on B Cells
(A) Coexpression of DC-SIGN and CD23 on B cells from healthy,
HIV-1–seronegative donors (n¼20). Hour 0 [T0]¼0 h; hour 24 [T24]
¼ 24 h.
(B) Time-dependent expression of DC-SIGN and CD23 in response to
IL-4 and CD40L. Puriﬁed B cells from a normal donor were cultured
in the presence of IL-4 or CD40L or a combination of the two.
Untreated cells were used as controls (NT). DC-SIGN and CD23
coexpression on activated B cells was greatest using a combination of
1,000 U/ml of IL4 and 1 lg/ml of CD40L for 24 h. Single
concentrations of 100, 500, and 10,000 U/ml of IL-4 and 0.1, 0.5,
and 10 lg/ml of CD40L induced similar, low levels of DC-SIGN
expression (unpublished data). Also, various combinations of these
concentrations of IL-4 and CD40L induced less DC-SIGN expression
than this combination (unpublished data).
Found at DOI: 10.1371/journal.ppat.0020070.sg001 (380 KB JPG).
Accession Numbers
The GenBank accession number (http://www.ncbi.nlm.nih.gov/
Genbank) for the gene mentioned in this paper is CD209
(NM_021155).
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